Tim FerrissHamilton Morris on Iboga, 5-MeO-DMT, the Power of Ritual, New Frontiers in Psychedelics, and More
CHAPTERS
- 5:06 – 7:00
Hamilton Morris returns: background, scope, and ground rules
Tim Ferriss introduces Hamilton Morris and frames the conversation as a wide-ranging update on psychedelics, chemistry, and culture. Tim also recaps prior topics and sets safety expectations, including a non-medical-advice disclaimer and a reminder that risks depend heavily on context and supervision.
- •Tim introduces Hamilton’s work and where to find it online
- •Tim recaps prior discussion topics (Shulgin, unsettling experiences, ibogaine, and more)
- •Tim emphasizes that risks are not only about the compound but also setting and supervision
- •Tim states a disclaimer: informational purposes only, not medical advice
- 7:00 – 20:39
Alexander Shulgin’s newly found 1987 class recordings and drug-policy context
Hamilton shares news about newly discovered tape recordings of Alexander “Sasha” Shulgin teaching a class in 1987, being published as a multi-volume set. He connects the timing to worsening U.S. drug policy, including MDMA’s scheduling and the Federal Analog Act, and describes why the material is unusually valuable.
- •Hamilton explains who Shulgin was and why his expertise was exceptional
- •Hamilton describes the lost class recordings being published as “The Nature of Drugs” via Transform Press
- •Hamilton ties 1987 to a turning point: MDMA’s scheduling and the Federal Analog Act
- •Hamilton argues Shulgin became more politically galvanized as restrictions tightened
- •Tim asks whether the audio might be released and suggests sharing excerpts on the podcast
- 20:39 – 28:03
Self-experimentation, “bias,” and why hiding drug experience can be harmful
Hamilton challenges the idea that personal experience with psychoactives inherently disqualifies researchers, comparing it to other fields where experience confers credibility. He argues that dishonesty and “closeting” may protect individuals short term but slows cultural change long term, while Tim echoes the value of public, non-anonymous support to reduce stigma.
- •Hamilton disputes claims that researcher drug experience automatically invalidates their work
- •Hamilton compares drug research to ethnomusicology and sports commentary to highlight inconsistency
- •Hamilton criticizes pressures to keep chemistry and use secret as a long-term losing strategy
- •Tim describes encouraging public (non-anonymous) philanthropy to avoid reinforcing stigma
- •Hamilton attributes some objections to cultural discomfort with pleasure and euphoria
- 28:03 – 33:06
Pioneers and practice: Oliver Sacks, Claudio Naranjo, and William Richards
Hamilton discusses prominent figures whose drug experiences were often hidden or anonymized, including Oliver Sacks and Carl Sagan. The conversation moves into Claudio Naranjo’s writing and William Richards’ work, including an emotionally intense example of end-of-life psychedelic therapy and the impact on families.
- •Hamilton says Oliver Sacks wrote about experiences while avoiding public acknowledgment of drug use
- •Hamilton cites Carl Sagan’s anonymous contribution to a cannabis discussion in a book
- •Hamilton and Tim discuss Claudio Naranjo’s book “The Healing Journey”
- •Hamilton recommends William Richards’ “Sacred Knowledge” and describes a moving end-of-life therapy segment he shared on YouTube
- •Hamilton reflects on how end-of-life peace can reduce trauma for surviving family members
- 33:06 – 46:12
What worries Hamilton: hype cycles, ketamine, cannabis, and scaling therapy quality
Hamilton outlines concerns about “hype phases” where limitations and harms are underappreciated, using ketamine as an example. He also questions whether heavy, constant cannabis intoxication will look different under future scrutiny and warns that extraordinary clinical results may rely on unusually skilled practitioners that are hard to replicate at scale.
- •Hamilton quotes Shulgin’s joke that ‘every drug has no side effects for the first five years’
- •Hamilton notes ketamine’s current hype and mentions known bladder risks under some circumstances
- •Hamilton predicts more scrutiny of constant high-level cannabis use and mentions cannabis hyperemesis disorder
- •Hamilton warns that top-tier therapists (like William Richards) are rare, so outcomes may not generalize as programs scale
- •Tim connects the concern to therapist replication and broader acceleration in research and business activity
- 46:12 – 50:23
Iboga and ibogaine: ritual power, opioid addiction, and how traditions adapt
Hamilton explains why iboga/ibogaine seems promising for substance use disorders, then describes his experience participating in Central West African iboga rituals. He emphasizes that Bwiti practices are evolving in response to newly widespread opioid use (notably tramadol) and recounts the origin story of ibogaine’s anti-addictive reputation in the U.S.
- •Hamilton describes iboga ritual as intensely stimulating: dancing, drumming, no sleep, and continuous exertion
- •Hamilton explains tramadol’s availability and how regulation and access shape ‘abuse potential’
- •Hamilton tells the story of Howard Lotsof discovering ibogaine’s anti-withdrawal/anti-addictive effects and devoting his life to it
- •Hamilton says Bwiti communities are adapting rituals to treat local opioid addiction despite that not being a historical use-case
- •Hamilton discusses cardiac risk concerns, noting ibogaine’s interaction with hERG channels and the need for careful dosing and observation
- 50:23 – 1:05:54
Conservation and sustainability: iboga harvesting pressures and ethical sourcing
The conversation turns to ecological impacts as global demand grows for psychoactive plants and animals. Hamilton expresses conflict about promoting iboga while acknowledging slow growth and destructive harvesting practices, and Tim references broader ethical considerations around scaling demand.
- •Hamilton argues increased popularity will burden natural reserves of iboga, ayahuasca ingredients, and toad venom
- •Hamilton notes iboga shrubs take years before roots can be harvested and says he often saw whole plants killed during harvesting
- •Hamilton mentions proposed alternatives like partial root harvesting and cultivation approaches, but says incentives and pricing matter
- •Hamilton stresses consumers must be willing to pay for responsibly sourced materials
- •Tim frames the issue as what happens if demand scales 10x–1000x and references his conservation-focused writing
- 1:05:54 – 1:12:04
Synthesis vs. wild harvesting: MDMA supply chains and 5-MeO-DMT from melatonin
Hamilton argues that many environmental harms attributed to drugs are artifacts of black-market prohibition rather than chemical necessity. Using MDMA and 5-MeO-DMT as examples, he describes how synthesis can reduce pressure on ecosystems and explains why some people still prefer animal-derived material due to symbolism and ‘natural’ associations.
- •Hamilton says deforestation linked to MDMA precursors is not chemically required; it’s driven by black-market constraints
- •Hamilton describes converting melatonin into 5-MeO-DMT and contrasts yields with ‘milking’ large numbers of toads
- •Hamilton discusses why people value toad-derived material (animist/vitalist symbolism) and how synthetic compounds could be treated with comparable care and reverence
- •Hamilton notes ‘natural vs. synthetic’ meaning is shaped by cultural value systems and can be changed
- •Tim adds that even if natural sources were perceived as ‘better,’ ecological harm may still be unjustifiable when alternatives are adequate
- 1:12:04 – 1:27:48
Sonoran Desert toad myths, 5-MeO-DMT’s unique risks, and the case for synthesis
Hamilton challenges claims of ancient indigenous use of Bufo alvarius venom as a psychedelic and explains how a misunderstood hypothesis helped inspire modern use in the 1980s. He and Tim then discuss why 5-MeO-DMT can be destabilizing and how its effects differ sharply from DMT despite the name similarity.
- •Hamilton says there is no solid evidence of a historical tradition of smoking Bufo alvarius venom for 5-MeO-DMT
- •Hamilton describes how an anthropological interpretation led Ken Nelson to investigate and, in effect, discover the practice in modern times
- •Tim clarifies the distinction between lack of toad-venom tradition and the existence of 5-MeO-DMT-containing plants in other contexts
- •Hamilton explains 5-MeO-DMT is experientially distinct: often not visual, can be dissociative and physically intense
- •Hamilton likens high-dose effects to a near-death experience and warns the name misleads people into assuming it’s ‘like DMT’
- 1:27:48 – 1:40:53
Xenon gas: ‘perfect anesthetic’ allure, clinic dangers, and a real-world horror story
Hamilton explains what xenon is, why it’s rare and expensive, and why anesthesiologists consider it unusually attractive as an anesthetic. He then recounts investigating xenon “therapy” clinics and describes alarming safety lapses involving unconscious patients, vomiting risk without fasting protocols, and inadequate supervision when staff also self-administered xenon.
- •Hamilton explains xenon’s rarity, high cost, rapid onset/recovery, and lack of known metabolism as reasons it’s seen as an exceptional anesthetic
- •Hamilton describes his first xenon experience and how clinics later emerged offering xenon for many conditions
- •Hamilton identifies key risks: administering to children without appropriate anesthesia-level oversight and occupational dependence risk
- •Hamilton describes a frightening incident where an unconscious patient vomited while strapped into a tight mask, highlighting aspiration danger without fasting protocols
- •Hamilton recounts an episode where the clinic proprietor used xenon and became unconscious while a patient was also unconscious and unmonitored, underscoring the need for more caution
- 1:40:53 – 1:52:03
Ritual as a therapeutic amplifier, future backlash fears, and Hamilton’s required reading
Hamilton reflects on how his thinking shifted from pure reductionism toward recognizing ritual as potentially as powerful as the substance itself, drawing lessons from the iboga ceremony’s collective responsibility and endurance demands. He also warns about media cycles turning from pro-psychedelic enthusiasm to backlash after high-profile adverse stories, then closes with reading recommendations spanning Shulgin’s books, Bwiti anthropology, mushrooms, cacti, and his Bufo alvarius booklet.
- •Hamilton says iboga taught him rituals can magnify therapeutic effects and describes ‘collective motivation’ during ceremony participation
- •Hamilton explores why ideas like ‘inner reserves of energy’ can feel empowering, even if easy to mock in other contexts
- •Hamilton notes emerging clinical rituals (e.g., objects and ceremonial elements) and asks how best practices can be developed
- •Hamilton worries today’s positive media cycle could flip after prominent negative incidents, repeating historical patterns
- •Hamilton recommends PiHKAL and TiHKAL first, cites an anthropology text titled “Bwiti,” suggests works by Terence McKenna and Paul Stamets for mushrooms, mentions “The Wizard of the Four Winds” for mescaline cacti, and points to his republished Ken Nelson Bufo booklet site
